Edgestream Partners L.P. Has $1.92 Million Stock Holdings in Hologic, Inc. $HOLX

Edgestream Partners L.P. lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 75.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,477 shares of the medical equipment provider’s stock after purchasing an additional 12,677 shares during the quarter. Edgestream Partners L.P.’s holdings in Hologic were worth $1,921,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Chung Wu Investment Group LLC bought a new stake in Hologic in the second quarter worth $26,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 273 shares during the last quarter. Loomis Sayles & Co. L P bought a new stake in shares of Hologic during the 2nd quarter worth about $33,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic during the 1st quarter valued at about $34,000. Finally, Cromwell Holdings LLC raised its stake in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. This represents a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. BNP Paribas cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research report on Friday, November 21st. Stephens cut shares of Hologic from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and upped their price objective for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. Evercore ISI set a $78.00 target price on shares of Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday, October 22nd. Five research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $79.67.

Hologic Trading Up 0.1%

Shares of HOLX stock opened at $74.97 on Friday. The firm has a market capitalization of $16.71 billion, a P/E ratio of 30.23, a price-to-earnings-growth ratio of 2.13 and a beta of 0.70. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $80.31. The firm’s fifty day simple moving average is $72.28 and its 200 day simple moving average is $67.60. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the business posted $1.01 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.